Molecular evolution of a C5aR antagonist against inflammatory disease
New anti-inflammatory drugs with fewer adverse effects than existing drugs may prove to be useful in the treatment of several inflammatory disorders. A critical step in acute inflammation is the infiltration of neutrophils into tissues. Therefore, molecules that target and inhibit this early inflammatory event are attractive to engineer to suit medical needs. The Chemotaxis Inhibitory Protein of